MINI FUTURE LONG - ELI LILLY & CO | Delayed Deutsche Boerse AG 05:20:58 2024-07-11 am EDT | ||
| 65.49 EUR | +0.34% |
|
| Current month | +3.42% | ||
| 1 month | +11.14% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 65.49 | +0.34% |
| 24-07-10 | 65.27 | +0.80% |
| 24-07-09 | 64.75 | +2.37% |
| 24-07-08 | 63.25 | +0.57% |
| 24-07-05 | 62.89 | +1.81% |
Delayed Quote Deutsche Boerse AG
Last update July 11, 2024 at 05:20 am EDT
More quotesStatic data
| Product type | Warrant Knock-Out con Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PH21VN |
| ISIN | DE000PH21VN3 |
| Date issued | 2021-06-30 |
| Strike | 233.7 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.21 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 65.75 € |
|---|---|
| Lowest since issue | 2.43 € |
| Spread | 0.15 € |
| Spread % | 0.23% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
939.8
USD
Average target price
874.8
USD
Spread / Average Target
-6.92%
- Stock Market
- Certificates
- Certificat
